Urogen Pharma (NASDAQ:URGN) Stock Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Analysts rate UroGen Pharma a “Moderate Buy”: Eight of ten covering firms recommend buying the stock, with an average 12-month price target of $53.38.
• Recent results disappointed: The company reported a quarterly loss of $0.03 per share and $89 million in revenue, both below the cited consensus estimates; shares were reported down 10.5%.
• Growth and pipeline catalysts remain: ZUSDURI generated $68 million in third-quarter revenue, up 35% from the prior quarter, and the FDA accepted UGN-103 for review with a June 14, 2027 decision target.

Urogen Pharma (NASDAQ:URGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $53.38.

Several equities analysts have recently weighed in on the company. Jefferies Financial Group restated a "buy" rating and issued a $56.00 target price on shares of Urogen Pharma in a research report on Thursday, September 10th. TD Cowen lifted their target price on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Guggenheim dropped their target price on shares of Urogen Pharma from $58.00 to $56.00 and set a "buy" rating for the company in a report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Urogen Pharma in a research report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of Urogen Pharma in a research note on Monday, October 19th.

Urogen Pharma Trading Down 10.5%

Shares of URGN stock opened at $25.73 on Friday. The stock has a 50 day moving average of $39.20 and a 200 day moving average of $31.50. The stock has a market cap of $1.26 billion, a P/E ratio of -19.49 and a beta of 1.68. Urogen Pharma has a twelve month low of $16.50 and a twelve month high of $50.81.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.14). The firm had revenue of $89.00 million during the quarter, compared to analyst estimates of $89.92 million. On average, research analysts predict that Urogen Pharma will post -0.20 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Chris Degnan sold 2,202 shares of the business's stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $36.69, for a total transaction of $80,791.38. Following the transaction, the chief financial officer directly owned 4,561 shares in the company, valued at $167,343.09. The trade was a 32.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Jason Smith sold 1,519 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the sale, the general counsel directly owned 53,141 shares of the company's stock, valued at approximately $2,260,618.14. This represents a 2.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 65,269 shares of company stock valued at $3,037,646 in the last ninety days. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Urogen Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of URGN. Partners Capital Investment Group LLP purchased a new stake in shares of Urogen Pharma in the 2nd quarter valued at approximately $566,000. Legal & General Group Plc acquired a new stake in shares of Urogen Pharma during the 2nd quarter worth approximately $1,319,000. California State Teachers Retirement System raised its position in shares of Urogen Pharma by 1,605.5% during the 1st quarter. California State Teachers Retirement System now owns 38,750 shares of the company's stock valued at $697,000 after buying an additional 36,478 shares during the period. Elmind Capital LP purchased a new stake in shares of Urogen Pharma during the 2nd quarter valued at approximately $4,416,000. Finally, Rice Hall James & Associates LLC purchased a new stake in shares of Urogen Pharma during the 2nd quarter valued at approximately $11,064,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Key Urogen Pharma News

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: ZUSDURI generated $68 million in third-quarter revenue, up 35% from the prior quarter. UroGen also said repeat prescribers accounted for a growing share of ZUSDURI writers. UroGen third-quarter results
• Positive Sentiment: The FDA accepted UroGen’s UGN-103 application for review and set a June 14, 2027 target decision date, providing a potential future catalyst. The company also reported that the first patient was dosed in its UGN-501 Phase 1 trial. UroGen third-quarter results
• Neutral Sentiment: Guggenheim lowered its price target to $56 from $58 but maintained a Buy rating, signaling continued optimism despite the reduced target. Guggenheim rating
• Negative Sentiment: Investors focused on UroGen’s reduced FY2026 guidance and quarterly results that fell short of analyst expectations: reported EPS was a loss of $0.03 versus the cited consensus estimate of $0.11, while revenue of $89 million was slightly below estimates. UroGen Q3 results and guidance

Urogen Pharma Company Profile

UroGen Pharma Ltd. NASDAQ: URGN is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company's therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen's primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen's proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.